MCF Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

MCF Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-446	Closed	-$7.4K	–	1384
2025 Q4	$7.4K	Buy	+446	New	+$6.37K	﹤0.01%	891

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

MCF Advisors's PHAT Position: Q1 2026 in Review

MCF Advisors sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 446 shares — an estimated $7.4K sold.

MCF Advisors first reported a position in PHAT in Q4 2025 and held it in 1 quarter. The position peaked at $7.4K in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

MCF Advisors reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
MCF Advisors sold 446 Phathom Pharmaceuticals shares in Q1 2026, an estimated $7.4K.
MCF Advisors first reported a position in Phathom Pharmaceuticals in Q4 2025 and held it in 1 quarter.
MCF Advisors's Phathom Pharmaceuticals position peaked at $7.4K in Q4 2025.
174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on MCF Advisors's 13F filing for Q1 2026, filed 11 May 2026.